RxDoctor Payments Data

Jasmine Singh

Nurse Practitioner · Milford, MINPI 1235642919

Payments from drug & device makers

$1,614in general payments, 2019–2025

Across 74 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$395
  • Edwards Lifesciences$206
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
  • Merck$161
  • Amgen$141
  • Atricure, Inc.$123
  • plus $416 from 10 others

What the payments were for

  • Food & beverage$1,614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,614 in reported general payments places this provider in the 85th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$44,273
Medicare patients
270
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban403$572,048
EntrestoSacubitril/Valsartan218$331,343
XareltoRivaroxaban173$198,520
JardianceEmpagliflozin51$63,052
MultaqDronedarone Hcl19$41,632
Repatha SyringeEvolocumab46$32,095
Repatha SureclickEvolocumab31$25,553
BrilintaTicagrelor23$21,683
FarxigaDapagliflozin Propanediol15$17,428
NexletolBempedoic Acid17$9,883
Atorvastatin Calcium515$8,288
Valsartan168$7,423
Metoprolol Succinate347$6,575
ClopidogrelClopidogrel Bisulfate241$5,645
Isosorbide Mononitrate ErIsosorbide Mononitrate224$4,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$572,048403 claims
NovartisEntresto$395$331,343218 claims
Johnson & JohnsonXarelto$24$198,520173 claims
Boehringer IngelheimJardiance$104$63,05251 claims
AstraZenecaBrilinta, Farxiga$91$39,11238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Milford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →